R
Raheleh Roudi
Researcher at Iran University of Medical Sciences
Publications - 55
Citations - 1306
Raheleh Roudi is an academic researcher from Iran University of Medical Sciences. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 16, co-authored 46 publications receiving 755 citations. Previous affiliations of Raheleh Roudi include University of Minnesota.
Papers
More filters
Journal ArticleDOI
Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
Xiaoying Sun,Raheleh Roudi,Ting Dai,Shangya Chen,Bin Fan,Hongjin Li,Yaqiong Zhou,Min Zhou,Bo Zhu,Chengqian Yin,Bin Li,Xin Li +11 more
TL;DR: The specificity of irAEs was closely associated with the mechanism of PD-1/PD-L1 antibodies involved in restarting anticancer immune attacks and comprehensive understanding, timely detection, and effective management could improve the compliance of patients and guide the interruption of treatment.
Journal ArticleDOI
Antimicrobial Peptides As Biologic and Immunotherapeutic Agents against Cancer: A Comprehensive Overview
TL;DR: This review explicates the biochemical underpinnings of their tumor-selectivity, and discusses results of recent clinical trials (outside of oncologic indications) which substantiate their safety and tolerability profiles.
Journal ArticleDOI
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
TL;DR: In this paper, the authors summarize state-of-the-art understanding of the molecular mechanisms underlining CTLA-4 immune regulation and the correlation of the ICI response with T-lymphocyte-associated protein 4 expression in Treg cells from preclinical and clinical studies.
Journal ArticleDOI
Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.
Alfredo Tartarone,Giandomenico Roviello,Rosa Lerose,Raheleh Roudi,Michele Aieta,Pietro Zoppoli +5 more
TL;DR: This meta-analysis confirms the superiority of ICIs over docetaxel in pretreated non-small-cell lung cancer patients and would indicate a slight benefit from anti-PD-1 than fromAnti- PD-L1 inhibitors, always keeping in mind the possible biases of this indirect comparison.
Journal ArticleDOI
Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes
TL;DR: ALDH1high/CD133high phenotype can be considered as a CSC marker in some lung cancer subtypes, as over-expression of both ALDH1 and CD133 markers was exclusively found in SCC and ADC.